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Plasma levels of glucose, insulin and glucagon were
measured at various time intervals after pancreatic
duct ligation (PDL) in rabbits. Two hyperglycemic
periods were observed: one between 15-90 days
(peak at 30 days of 15.1 1.2mmol/1, p <0.01), and
the other at 450 days (11.2 +_. 0.5 mmol/1, p < 0.02). The
first hyperglycemic episode was significantly corre-
lated with both hypoinsulinemia (41.8 +__8pmol/1,
r=-0.94, p<0.01) and hyperglucagonemia (232___
21ng/1, r 0.95, p<0.01). However, the late hyper-
glycemic phase (450 days), which was not accompa-
nied by hypoinsulinemia, was observed after the
hyperglucagonemia (390 days) produced by abun-
dant immunostained A-cells giving rise to a 3-fold
increase in pancreatic glucagon stores. The insulin
and glucagon responses to glucose loading at 180,
270 and 450 days reflected the insensitivity of B- and
A-cells to glucose. The PDL rabbit model with
chronic and severe glycemic disorders due to the
predominant role of glucagon mimicked key fea-
tures of the NIDDM syndrome secondary to
exocrine disease.
Keywords: Rabbit; Pancreatic duct ligation (PDL); Insulin;
Glucagon; Intravenous glucose tolerance test (IVGTT); Intra-
venous (i.v.); Immunocytochemistry; Non-insulin-dependent
diabetes mellitus (NIDDM)
INTRODUCTION
Modifications in islet cell mass are demonstrated
to be largely responsible for the glycemic disturb-
ances, and especially the hyperglycemia, in non-
insulin-dependent diabetic (NIDDM) GK rats, Ill
spontaneously diabetic Chinese hamsters I21 and
secondary to pancreatitis.TM or fibro-calculous-
pancreatic diabetes (FCPD). I41 Over the past two
decades, hyperglycemia-related hyperglucagone-
mia has also been observed in NIDDM patients,
streptozotocin rats [6] and alloxan-diabetic dogs, [7]
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as well as in chronic pancreatitis. I81 Glucagon is
found to cause the hyperglycemia in diabetic
diseases by increasing hepatic glucose output
(HGO), which stimulates gluconeogenesis in fast-
ing NIDDM. I91 Moreover, the hyperglucagonemia
of diabetes may be accounted for by defects
in primary A- and B-cells I11 as well as by an
impaired insulin secretion.
In a previous report,I11 we described the non-
insulin-dependent diabetogenic effects following
pancreatic duct ligation (PDL) in the rabbit.I11
The main short-term glycemic disorders were a
transient hyperglycemia and glucose intoler-
ance I11 concomitant with dissociation I121 and
regeneration of the Langerhans islet cells during
the first month. [13] The destruction of the islet
architecture led to morphological and metabolic
changes[4,151 notably at the time of minimum
mass of B-cells (day 30). By the 5th and 35th
days, the impairment in insulin secretion in the
isolated perfused pancreas is characterized by
loss of the early peak insulin release in response
to glucose stimulation and the abolition of the
potentiating effect of glucose on the arginine-
induced secretion. I161 These effects resemble
those noted in NIDDM, I171 FCPD,I81 acute pan-
creatitis,I191 and adult GK rats.I21
The present study was designed to: (1)
characterize glycemia and glucose tolerance
after long-term pancreatic duct ligation, to discern
relationships between glucose and insulin, glu-
cose and/or glucagon in plasma, and correlations
of plasma levels of these two hormones with pan-
creatic stores (2) study hormone regulation dur-
ing regeneration and recasting of the endocrine
parenchyma (3) compare this model system with
NIDDM in humans and animals.
MATERIALS AND METHODS
Pancreatic Duct Ligation
Adult male rabbits (Cuniculus oryctolagus-pro-
vided by a licensed supplier) of 14-15 weeks,
weighing 2.5 kg were fed with a commercial
diet (U.EA.C.-France) that contained 14% w/w
protein. Food and water were available ad libi-
turn. The rabbits were anesthetized with sodium
pentobarbital 0.5ml.kg body weight (Sanofi
Health Animal Nutrition, 33501 Libourne cedex,
France) by a single i.v. injection into the
marginal vein of the ear. After laparatomy, the
single duct was cut in between a double ligation
placed at its opening into the duodenum, 40 cm
from the pylorus in the PDL group, while the
pancreas was simply handled in the control
animals (C group).I21 All animal experiments
have been approved by the authorities of the
Ministry of Agriculture and Forestry: Direction
of Health and Animal Protection (personal
agreement n 04411).
Sampling and Analytical Procedures
Plasma glucose, insulin and glucagon concentra-
tions were determined in both groups. The non-
fasting rabbits were monitored at 0, 15, 30, 60,
90, 120, 180, 240, 340, 390 and 450 days after
operation (20 C animals and 30 PDL animals).
Blood samples were collected on EDTA +
10ml/1.5ml Iniprol (106 I.U.) (Choay Laborato-
ry, 75782 Paris Cedex 16, France) from the mar-
ginal vein of the ear at 9.00 a.m.
The intravenous glucose tolerance test
(IVGTT) was carried out at 180, 270 and 450
days on 8 C and 10 PDL rabbits. A glucose load
was administered to the restrained rabbits by
one i.v. injection of glucose 0.5g/kg into the
marginal vein of the ear. Blood was sampled
from the other ear, 2min before the injection of
glucose (time 0) and 5, 30, 60 and 90 min there-
after.
Insulin and glucagon pancreatic stores were
determined at 30 and 450 days. Four C and eight
PDL animals per period were killed quickly
and bled. Pancreatic tissue was minced in 10
volumes of an absolute alcohol/HC1/distilled
water solution (250/5/78 v/v). The pancreas
was crushed at 4C in an Ultra-Turrax apparatus
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(10,000 rpm for 2 min) followed by 10 strokes (20
sec each) in a Teflon glass Potter-type homoge-
nizer and maintained at 4C for four days then
centrifuged (5000rpm for 15min). The super-
natant was used at a final dilution of 1/5000 in
0.1 M PBS buffer, pH 7.4.
Biochemistry
Plasma glucose was measured by an enzymatic
method (glucose oxidase-GOD-PAP, Boehringer
Mannheim, 38240 Meylan Cedex, France) in a
COBAS-BIO autoanalyzer.
Immunoreactive insulin from 100 ml of plasma
was determined by RIA using the SB-INSI-5
assay kit (Cis bio International, Oris Industry Co,
91192 Gif sur Yvette cedex, France), suitable for
humans and animals, showing a weak reaction
with proinsulin (3%). The detection limit was
given as 2.50 + 0.27 mU/ml by the manufacturer.
Plasma immunoreactive glucagon was mea-
sured by RIA according to the technique of
Kervran et al. [22] using goat GAN antiserum
(diluted 1/5000) and monoiodinated (125I-labeled)
glucagon (generous gifts from Pr. A. Kervran,
Montpellier, France). GAN antiserum incubated
for five days at 4C recognized the -COOH ter-
minal of pancreatic glucagon. Samples of 100 ml
were used for each determination with 250
dextran-charcoal suspension, after 15min of
magnetic agitation at 4C, 2 ml phosphate buffer
0.05 M were added to each tube. The radioactive
precipitate was obtained after separation by cen-
trifugation (6 min at 3200 rpm at 4C) and count-
ed in a gamma Counter 5000 (Packard Instr. Paris,
France). The experimental detection limit report-
ed for the technique was < 0.7 fmol/500 ml.
Statistical Methods
The data were expressed as means +__ SEM and
compared byANOVA and Student’s unpaired and
paired tests. Differences were considered signifi-
cant at p < 0.05. For the determination of hormo-
nal insulin, pancreatic glucagon stores and IVGTT,
data from C rabbits were pooled, since no differ-
ences were observed at the different time points.
Immunocytochemistry
Samples from the pancreas (tail) of 27 rabbits
(4 C and 5 PDL per period), used for the bio-
chemical determinations at 180, 270 and 450
days, were processed as described elsewhere. [141
RESULTS
Glucose, insulin and glucagon were determined
in the plasma of both control and PDL rabbits
over a period of 450 days after operation. The
glucose concentrations in the C group (Fig. la)
ranged from 8.1 + 0.7mmol/1 to 10.2 + 0.8mmol/1
throughout the experiment. In the PDL group,
two transient periods of significantly high values
were noted, one at 15-90 days (p < 0.01), and the
other at 450 days (p < 0.02).
Insulin levels (Fig. lb) were significantly
reduced on the 30th day (41.8+7.6pmol/1,
p < 0.01) and the 180th day (83.8 + 3.1pmol/1,
p < 0.02) compared to the control animals whose
insulin profile progressed with alternating peaks.
In the C group, glucagon concentrations were
158 16ng/1 throughout the experiment (Fig.
lc). After PDL, marked variations were observed
with two distinct peaks: the first at 30 days
(232___21ng/1, p<0.01) and the second at
390 to 450 days (225_25ng/1, p<0.01 and
199 + 20ng/1 p < 0.01, respectively), separated
by troughs that were below levels in the C group
(p<0.05) at 120 days (132 + 7ng/1) and 180
days (120 + 3 ng/1).
From days 0 to 120, plasma glucagon and glu-
cose were significantly correlated (r 0.91, p <
0.001), whereas in the late hyperglucagonemic
period, glucose release was elevated only at the
390th day, i.e., 50 days later than glucagon. Up to
60 days, negative correlations were observed
between circulating insulin and glucagon (r
-0.95, p<0.001), and between insulin and
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FIGURE 1 Comparative study of the concentrations of (a) plasma glucose (b) plasma insulin and (c) plasma glucagon in C
rabbits and P rabbits from 0 to 450 days post-ligation. Each point indicats the mean SEM values for 8 C and
22 to 8 PDL animals. *p < 0.05, **p < 0.02 and ***p 0.01.
glucose (r=-0.94, p<0.001), but there was
a positive correlation between glucose and
glucagon (r 0.95, p < 0.001).
The evolution of pancreatic insulin
and glucagon stores is illustrated in Figure 2.
In the PDL group, insulin had decreased






FIGURE 2 Comparison of insulin and glucagon concentra-
tions in pancreatic gland in C rabbits () and P rabbits (30
days 450 days ). Values given are mean SEM for 4
C to 8 PDL animals. ***p < 0.01.
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FIGURE 3 Intravenous glucose loading test (0.05g/kg).
Changes in plasma glucose response in C rabbits (---) and
P rabbits at 180 ), 270 and 450 days
post ligation. Each curve plots means SEM for 8 C to 10
animals. *p < 0.05 and **p ( 0.02.
2-fold at 30 days (p < 0.01) and 4-fold at 450
days (p(0.01), while glucagon was 3-fold
higher (p 0.01) than in the C group at 450
days.
After the IVGTT, plasma glucose in the C
group reached a peak at the 5th min then
returned to basal values 60 min later. At 180,
270 and 450 days, the PDL rabbits exhibited
the same profile, but with significantly higher
values up to 60 min (from p (0.05 to p (0.02)
(Fig. 3). Five min after injection, the insulin
responses to the IVGTT of both groups (Fig. 4)
reached a peak then returned to basal values at
90 min. The peak secretion in the PDL group
was reduced 2-fold at 180 days (p (0.01) and
5-fold at 270-450 days (p(0.01). In the C
group, glucagon had fallen to 50% of its initial
level at 60 min, and then rose above basal lev-
els at 90 min (Fig. 5). In the PDL group,












FIGURE 4 Intravenous glucose loading test (0.05g/kg).
Changes in plasma insulin response in C rabbits and
P rabbits at 180 ), 270 and 450 days
post-ligation. Each curve plots means SEM for 8 C to 10
PDL animals. *p ( 0.05 and ***p ( 0.01.








FIGURE 5 Intravenous glucose loading test (0.05g/kg).
Changes in plasma glucagon response in C rabbits
and P rabbits at 180 ), 270 and 450()
days post -ligation. Each curve plots means SEM for 8 C to
10 animals. *p < 0.05 and ***p < 0.01.
days by the 30th (p< 0.05) and 60th min
(p<0.01), whereas at 270 and 450 days, it
remained unchanged at all times after injection
of glucose.
The immunocytochemical observations on
A-cells are illustrated in Figure 6. In the C
group, immunostained cells for glucagon were
found mainly on the periphery of the islets
(Fig. 6a). After PDL, the marked A-cell
immunoreactivity enabled us to localize the
numerous changes in the long-term recasting
pancreas. At 180 days (Fig. 6b), some of the
A-cells were located irregularly around clus-
ters of unstained endocrine cells and scattered
among the fibro-connective tissue. At 270
days, a number of them were arranged in
a discontinuous thick mantle encircling the
clusters (Fig. 6c). Enlarged homologous and
heterologous A-cell areas were distributed
inside the fibrous tissue, which was itself
surrounded by adipose tissue at 450 days
(Fig. 6d).
DISCUSSION
Pancreatic duct ligation (PDL) in our rabbits
induced atrophy and fibrotic replacement of the
pancreatic acini, I121 consistent with most of the
effects produced by either duct ligation or occlu-
sion in various species. [23-25] However, its influ-
ence on the endocrine system was less in accord
with previous reports. [26,271 To our knowledge,
the rabbit is the only laboratory animal that pos-
sesses a single pancreatic duct, separated by 40
cm from the bile duct. [28] Its ligation leads to nei-
ther severe nutritional disorders nor obesity,I291
which may be accounted for by compensatory
digestive processes induced by microorgan-
isms I301 or intestinal mucosal enzyme activities,
which are thought to operate after PDL,I311 in
patients with cystic fibrosis [32] and those with
chronic pancreatic insufficiency associated with
diabetes mellitus. I331
In fact in rabbits, long-term pancreatic duct lig-
ation induces no visible pathological signs, apart
from a chronic and progressive diabetogenic
state leading to irreversible pathology. How-
ever, our findings differed from those of Hepner
et al. [341 who found blood glucose unchanged
between 2 and 12 months after ligation in rabbits.
This difference may be due to differences in
breed and experimental conditions. In mini-pigs,
pancreatic occlusion was not found to lead to
glycemic disorders until 9 months,I351 whereas in
rats, an increase in glycemia was described 5 to 8
months after ligation. I361
The comparative variations in glycemia and
insulinemia of the C and PDL rabbits are illus-
trated in Figures la,b. During the 1st month, the
elevated glucose levels in the C group could be
explained by the effects of the anesthesia and
laparotomy followed by operative stress, as
described in fasting sham rats. [37] The hyper-
glycemia in the PDL group was more marked
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FIGURE 6 Long-term immunoreactiveA cells in endocrine pancreas of control and pancreatic duct ligated rabbits. (a). Controls,A
cells (A) are placed essentially at the periphery and sometimes inside the islet of Langerhans (I). (Magnification 192). (b). 180
days, few A cells (A) are particularly well developed at the periphery of clusters (cl) or scattered among a fibroconnective tissue
(fct). (Magnification 480). (c). 270 days, maximum immunoreactivity of A cells (A) laid out in a thick mantle at the periphery of
non-stained B cell clusters (cl). (Magnification 480). (d). 450 days, intense immunoreactivity of numerous homologousA cell clus-
ters (A) inside a fibrous tissue (ft) and around pseudo-islets (PI) surrounded by numerous adipocytes (a). (Magnification 192).
than that found in previous data [111 with a maxi-
mum (15.1 + 1.2mmol/1) that correlated (r=
-0.94, p < 0.001) with the nadir in insulin levels
(42 +__ 8pmol/1) on day 30 (Fig. lb). The plasma
insulin and the insulin pancreatic store (200 +
7g/total pancreas) (Fig. 2) were around half
the levels in the C group (103+13pmol/1
plasma insulin, and 400 __+ 15g/total pancreas
weight). Such reductions in plasma insulin and
pancreatic insulin content have been described
in perinatal STZ rats I381 and GK rats I21 and are
thought to be the primary event in the progres-
sion of diabetes in NIDDM patients I391 and
NIDDM GK rats. Ill After PDL, the transient
hypoinsulinemic state is concomitant with a sig-
nificant decline (-75%) in number of B-cells by
the 30th day. I141 During the first month post-liga-
tion, fibrosis was responsible for the dissociation
of islets and the scattering of insular cells (B, A
and D), leading to B-cell necrosis and partial
degranulationIlll with a reduction in nuclear and
cytoplasmic areas. [141 It was clear that the reduc-
tion in B-cell mass led to the hypoinsulinemia
and the loss of insulin stores indicating that the
regenerated B-cells became mature later.
From the 90th day, in the PDL group, glucose
returned to its basal level, which was slightly
higher than in the C group (Fig. la). At the same
time, the basal plasma insulin did not differ sig-
nificantly from that in the C group (Fig. lb),
which was indicative of regeneration of B-cells
and their ability to secrete insulin. However, the
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observed insulinemia might have stemmed from
the accumulation of large amounts of proinsulin,
which has been found associated with the insulin
defects in diabetics.I41 After PDL, during regen-
eration of B-cells, proinsulin may not be fully
cleaved into active insulin. Moreover, as the abil-
ity of the basal plasma insulin to maintain eug-
lycemia from the 90th day was time-limited, the
available insulin was unable to prevent the later
period of hyperglycemia (450 days). The plasma
glucose increased by about 25% with respect to
that observed in the C group, and rose continu-
ously until 540 days (unpublished observations).
At 450 days, the four-fold less insulin in pancre-
atic stores in the PDL group (101_ 121xg vs.
400 + 15bg/ total pancreas in the C group)
(Fig. 2) indicated an inability of the regenerated
B-cells to restore the initial pancreatic store giv-
ing rise to the long-term insulin impairment.
The changes in plasma glucagon levels throw
light on other aspects of the glycemic defects
after PDL (Fig. lc). The basal plasma glucagon of
158 _
15ng/1 in the C group remained relatively
stable over 450 days. It ranges from 120pg/ml
in humans I181 and 180pg/ml in dogs I411 to
323pg/ml and 331pg/ml in Wistar and GK rats,
respectively (1). In contrast, our rabbits exhibit-
ed two significant hyperglucagonemic states
(Fig. lc) after PDL. The first, from 15 to 60 days
appeared with a peak (232 +- 21.0ng/1, p < 0.01)
at day 30. Immunocytochemical observations I141
have shown that as the B-cells are destroyed by
the 30th day, the A-cells are preserved with
hypertrophy of their nuclear areas, which is a
reflection of hyperactivity. Moreover, the lack of
alteration in pancreatic glucagon stores (Fig. 2)
indicated that the A-cells released rather than
stored glucagon. Their hyperactivity was proba-
bly the consequence of a loss of glucagon-
inhibiting action from the dispersal of B-and
D-cells in fibrotic tissue. [42’43] A hyperglucagone-
mic state had been reported in NIDDM
patients,[44,45] in diabetic rats,[46] dogs,[47] and
db/db mice. I481 In contrast to fetuses, adult GK
ratsIll and neonatal STZ diabetic rats,I381 basal
plasma glucagon was found to be unchanged
and even lower in mini-pigs after pancreatic
occlusion. I351 The second hyperglucagonemic
state (Fig. lc) between 390 days (225 25.4ng/1,
p < 0.01) and 450 days (199 20ng/1, p < 0.01)
being about 50% higher than the levels in the C
group, was consistent with the morphological
changes in the regenerated cells illustrated in
Figure 6. There was an increase in number of
immunostained A-cells, which formed a thick
crown surrounding the clusters of B-cells called
pseudo-islets. [141 These features were most
marked from 270 to 450 days (Figs. 6c,d) and
probably caused the increase in both glucagone-
mia and pancreatic glucagon content (3-fold at
450 days) (Fig. 2). The ability of the A-cells to
continuously synthesize glucagon by releasing
and storing it, showed that the regenerated insu-
lar A-cells had escaped normal endocrine regu-
lation in the pseudo-islets. The simultaneous
decrease in B-cells and increase in A-cells after
PDL were similar to the evolution of pancreatic
islet cells in either spontaneous [49] or induced I501
type 2 diabetes. In our experimental model,
these events could be attributed to glucagonoma
accounting for the uncontrolled glucagon release
giving rise to an irreversible diabetogenic effect,
as noted in the course of NIDDM in man. I511
When comparing the long-term (from 0 to 450
days) plasma glucagon profile (Fig. lc) with glu-
cose levels (Fig. la), the insulinemia (Fig. lb)
was taken into account. From 0 to 120 days,
there was a significant correlation between glu-
cose and glucagon levels (r 0.91, p < 0.001)
corresponding to the hyperglycemic and
insulinopenic episodes. Up to 60 days, there
was a positive correlation (r 0.95, p < 0.001)
between plasma glucose and glucagon, but
a negative correlation between glucose and
insulin (r=-0.94, p<0.001), and between
insulin and glucagon (r=-0.95, p < 0.01). By
contrast, in STZ diabetic rats, there is a concomi-
tant hyperglucagonemia and hyperglycemia
with a delay in the insulinopenia. I521 After PDL,
it was not clear which hormone was responsible
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for the first hyperglycemic period, although
the combined effects of hypoinsulinemia and
hyperglucagonemia enhance HGO. In diabetic
patients, hyperglucagonemia involves a primary
insulinopenia whose action was on gluconeo-
genesis rather than glycogenolysis [53] leading to
excessive hepatic glucose production. I541
There was another possible relationship be-
tween the second hyperglucagonemic episode
(Fig. lc) at 340-450 days and the hyperglycemic
one starting 50 days later (Fig. la), without
hypoinsulinemia (Fig. lb). In fact, glucose was
released to a lesser extent and was delayed with
respect to glucagon, whereas glucagon levels
were identical to those of the first. A new regula-
tion of the glucagon response may exist in the
HGO when the plasma insulin had returned to
its basal level producing its inhibiting effects.
These observations would suggest that PDL did
not lead to long-term insulin resistance. Despite
the hyperglucagonemia, the indirect action of
insulin in suppressing endogenous glucose pro-
duction is considered to be a dominant event in
human type 2 diabetes I551 and STZ rats. I561
The opposite actions of glucagon (Fig. lc) and
insulin (Fig. lb) in maintaining euglycemia be-
tween the two hyperglycemic phases (Fig. la)
from 120 to 390 days was indicative of a certain
stability and functionality of the regenerated
islets cells during a limited post-ligation period.
However, the IVGTT data demonstrated
aggravated intolerance to glucose in the long-
term after PDL despite the presence of basal plas-
ma insulin levels. At 180, 270 and 450 days, 5, 30,
and 60 min after glucose injection, plasma glu-
cose levels remained significantly higher than
those measured in the C group (Fig. 3). At 5 min,
the insulin response appeared to decline marked-
ly at 180 and 270-450 days (2-fold to 5-fold,
respectively) (Fig. 4), corroborating the impaired
insulin responses observed at 5, 15 and 30
days by previous data. Illl This has been typical-
ly linked with NIDDM and FCPD diseases
in humans, I181 rats (57-58), and with chron-
ic pancreatitis. I31 The progressive reduction in
insulin response after PDL is consistent with the
immunocytological findings (Fig. 6). At 180 days
post-ligation (Fig. 6b), when the insulin response
was least reduced (2-fold), we noted some clus-
ters of unstained B-cells with a few stained
A-cells leading an aspect similar to the original
islets. However, the markedly impaired insulin
release observed at 270 days, and especially at
450 days (Fig. 4) illustrated the insensitivity of
B-cells in the pseudo-islets accompanied by a
decrease in pancreatic insulin stores (about 4-fold
vs. controls) (Fig. 2). These observations indicat-
ed that the regenerated B-cell mass was unable to
synthesize active insulin in response to stimula-
tion and could not even maintain pancreatic
stores (Fig. lb). This deficit in insulin secretion in
regenerated B-cells has also been described in
Zucker diabetic fatty (ZDF)[59] and STZ rats.I61
As the glucagon response to the IVGTT in
rabbits has not yet been described, these ex-
periments (Fig. 5) supplied further information
about A-cell function in the regenerated islets
greatly enriched by A-cells (Figs. 6c,d). In the C
group, the glucagon profile was similar to that
of humans I81 i.e., with an initial progressive fall
up to 60 min followed by a significant increase
at 90 min (Fig. 5). After PDL (Fig. 5), by 180
days, the plasma glucagon response declined at
5 min as in controls, but there was a significant
increase from 30 min (p < 0.05) to 60 min (p <
0.01). The same hyperglucagonemic profile has
been described in diabetic dogs [41] after oral glu-
cose administration. After PDL, on appearance
of new islets near the original structure (Fig. 6b),
the glucose sensitivity of both A- anc B-cells was
found to be less affected than at 270-450 days
(Figs. 6c,d). At these later periods, the nearly
horizontal profile (Fig. 5) indicated that the plas-
ma glucagon response was abolished, demon-
strating the insensitivity of A-cells to glucose.
These results showed that the regenerated islets
with the numerous A-cells associated with an
elevated (3-fold) pancreatic glucagon content
were unable to reduce production of glucagon.
The horizontal glucagon profile in response to
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IVGTT after PDL was comparable to that found
in tropical FCPD I181 and NIDDM patients I611 as
well as in chronic pancreatitis. I81
These experiments demonstrated that in
rabbits, abnormalities in hormonal responses of
islet cell due to alterations inherent in the recon-
stitution of pseudo-islet cells were comparable
to the impaired hormone responses in NIDDM
patients.[62]
The defects after PDL mimicked the main
features of the NIDDM syndrome, FCPD and
pancreatitis in both humans and animals, and
throw more light on the relationships between
the antagonistic pancreatic hormones in the
regulation of blood glucose. The PDL rabbit
would thus appear to be a suitable experimen-
tal model for further investigations on the
pathophysiology and treatment of pancreatic
disorders.
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